Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

mTOR inhibition improves the immunomodulatory properties of human bone marrow mesenchymal stem cells by inducing COX-2 and PGE2.

Wang B, Lin Y, Hu Y, Shan W, Liu S, Xu Y, Zhang H, Cai S, Yu X, Cai Z, Huang H.

Stem Cell Res Ther. 2017 Dec 29;8(1):292. doi: 10.1186/s13287-017-0744-6.

2.

mTOR-Dependent Cell Proliferation in the Brain.

Ryskalin L, Lazzeri G, Flaibani M, Biagioni F, Gambardella S, Frati A, Fornai F.

Biomed Res Int. 2017;2017:7082696. doi: 10.1155/2017/7082696. Epub 2017 Nov 13. Review.

3.

Metabolic reprogramming ensures cancer cell survival despite oncogenic signaling blockade.

Lue HW, Podolak J, Kolahi K, Cheng L, Rao S, Garg D, Xue CH, Rantala JK, Tyner JW, Thornburg KL, Martinez-Acevedo A, Liu JJ, Amling CL, Truillet C, Louie SM, Anderson KE, Evans MJ, O'Donnell VB, Nomura DK, Drake JM, Ritz A, Thomas GV.

Genes Dev. 2017 Oct 15;31(20):2067-2084. doi: 10.1101/gad.305292.117. Epub 2017 Nov 14.

PMID:
29138276
4.

Characterization of the transcriptional and metabolic responses of pediatric high grade gliomas to mTOR-HIF-1α axis inhibition.

Nguyen A, Moussallieh FM, Mackay A, Cicek AE, Coca A, Chenard MP, Weingertner N, Lhermitte B, Letouzé E, Guérin E, Pencreach E, Jannier S, Guenot D, Namer IJ, Jones C, Entz-Werlé N.

Oncotarget. 2017 Mar 23;8(42):71597-71617. doi: 10.18632/oncotarget.16500. eCollection 2017 Sep 22.

5.

Targeting mTORC2 component rictor inhibits cell proliferation and promotes apoptosis in gastric cancer.

Bian YH, Xu J, Zhao WY, Zhang ZZ, Tu L, Cao H, Zhang ZG.

Am J Transl Res. 2017 Sep 15;9(9):4317-4330. eCollection 2017.

6.

EGF regulation of proximal tubule cell proliferation and VEGF-A secretion.

Zepeda-Orozco D, Wen HM, Hamilton BA, Raikwar NS, Thomas CP.

Physiol Rep. 2017 Sep;5(18). pii: e13453. doi: 10.14814/phy2.13453. Epub 2017 Sep 27.

7.

Inhibition of p70S6K does not mimic the enhancement of Akt phosphorylation by rapamycin.

Wang X, Yue P, Tao H, Sun SY.

Heliyon. 2017 Aug 8;3(8):e00378. doi: 10.1016/j.heliyon.2017.e00378. eCollection 2017 Aug.

8.

Conditional cell reprogramming involves non-canonical β-catenin activation and mTOR-mediated inactivation of Akt.

Suprynowicz FA, Kamonjoh CM, Krawczyk E, Agarwal S, Wellstein A, Agboke FA, Choudhury S, Liu X, Schlegel R.

PLoS One. 2017 Jul 10;12(7):e0180897. doi: 10.1371/journal.pone.0180897. eCollection 2017.

9.

Formal Modeling of mTOR Associated Biological Regulatory Network Reveals Novel Therapeutic Strategy for the Treatment of Cancer.

Bibi Z, Ahmad J, Siddiqa A, Paracha RZ, Saeed T, Ali A, Janjua HA, Ullah S, Ben Abdallah E, Roux O.

Front Physiol. 2017 Jun 13;8:416. doi: 10.3389/fphys.2017.00416. eCollection 2017.

11.

Activating MAPK1 (ERK2) mutation in an aggressive case of disseminated juvenile xanthogranuloma.

Chakraborty R, Hampton OA, Abhyankar H, Zinn DJ, Grimes A, Skull B, Eckstein O, Mahmood N, Wheeler DA, Lopez-Terrada D, Peters TL, Hicks JM, Elghetany T, Krance R, Poulikakos PI, Merad M, McClain KL, Allen CE, Parsons DW.

Oncotarget. 2017 Jul 11;8(28):46065-46070. doi: 10.18632/oncotarget.17521.

12.

AKT/PKB Signaling: Navigating the Network.

Manning BD, Toker A.

Cell. 2017 Apr 20;169(3):381-405. doi: 10.1016/j.cell.2017.04.001. Review.

PMID:
28431241
13.

Role of mTORC1-S6K1 signaling pathway in regulation of hematopoietic stem cell and acute myeloid leukemia.

Ghosh J, Kapur R.

Exp Hematol. 2017 Jun;50:13-21. doi: 10.1016/j.exphem.2017.02.004. Epub 2017 Mar 22. Review.

PMID:
28342808
14.

Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity.

Faes S, Demartines N, Dormond O.

Oxid Med Cell Longev. 2017;2017:1726078. doi: 10.1155/2017/1726078. Epub 2017 Feb 9. Review.

15.

mTORC2 (Rictor) in Alzheimer's Disease and Reversal of Amyloid-β Expression-Induced Insulin Resistance and Toxicity in Rat Primary Cortical Neurons.

Lee HK, Kwon B, Lemere CA, de la Monte S, Itamura K, Ha AY, Querfurth HW.

J Alzheimers Dis. 2017;56(3):1015-1036. doi: 10.3233/JAD-161029.

16.

Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.

Fourneaux B, Chaire V, Lucchesi C, Karanian M, Pineau R, Laroche-Clary A, Italiano A.

Oncotarget. 2017 Jan 31;8(5):7878-7890. doi: 10.18632/oncotarget.13987.

17.

Cross-talks via mTORC2 can explain enhanced activation in response to insulin in diabetic patients.

Magnusson R, Gustafsson M, Cedersund G, Strålfors P, Nyman E.

Biosci Rep. 2017 Jan 24;37(1). pii: BSR20160514. doi: 10.1042/BSR20160514. Print 2017 Feb 28.

18.

Rapamycin inhibits mTOR/p70S6K activation in CA3 region of the hippocampus of the rat and impairs long term memory.

Lana D, Di Russo J, Mello T, Wenk GL, Giovannini MG.

Neurobiol Learn Mem. 2017 Jan;137:15-26. doi: 10.1016/j.nlm.2016.11.006. Epub 2016 Nov 10.

19.

Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives.

Ong PS, Wang LZ, Dai X, Tseng SH, Loo SJ, Sethi G.

Front Pharmacol. 2016 Oct 25;7:395. eCollection 2016. Review.

20.

From Nutrient to MicroRNA: a Novel Insight into Cell Signaling Involved in Skeletal Muscle Development and Disease.

Zhang Y, Yu B, He J, Chen D.

Int J Biol Sci. 2016 Oct 17;12(10):1247-1261. eCollection 2016. Review.

Supplemental Content

Support Center